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Minn
Purpose: To review the indications and results of open surgical and endovascular treatment for ureteral-iliac artery fistula
(UIAF).
Methods: We reviewed the clinical data of 20 consecutive patients treated for 21 UIAFs between 1996 and 2010. Since
2004, iliac artery stent grafts were the primary treatment except for complex fistulas with enteric contamination or
abscess. Endpoints were early morbidity and mortality, patient survival, vessel or graft patency, freedom from vascular or
stent graft/graft infection, and freedom from recurrent bleeding.
Results:There were 20 patients, 15 females, and five males, with mean age of 6313 years. Predisposing factors for UIAF
were prior tumor resection in 18 patients, radiation in 15, ureteral stents in 15, ileal conduits in four, and ileofemoral
grafts in three. All patients presented with hematuria, which was massive in 10. Treatment included iliac stent grafts in
11 patients/12 fistulas (55%), with internal iliac artery (IAA) exclusion in nine, femoral crossover graft with IAA
exclusion in five, direct arterial repair in three, and ureteral exclusion with percutaneous nephrostomy and no arterial
repair in one. There were no early deaths. Five of eight patients treated by open surgical repair developed complications,
which included enterocutaneous fistula in three and superficial wound infection in two. Four patients (36%) treated by
iliac stent grafts had complications, including pneumonia, non-ST segment elevation myocardial infarction, buttock
claudication, and early stent occlusion in one each. After a median follow-up of 26 months, no one had recurrent massive
hematuria, but minor bleeding was reported in three. Patient survival at 5 years was 42% compared with 93% for the
general population (P< .001). Freedom from any recurrent bleeding at 3 years was 76%. In the stent graft group, primary
and secondary patency rates and freedom from stent graft infection at 3 years were 81%, 92%, and 100%.
Conclusions:UIAF is a rare complication associated with prior tumor resection, radiation, and indwelling ureteral stents.
In select patients without enteric communication or abscess, iliac artery stent grafts are safe and effective treatment, and
carry a low risk of recurrent massive hematuria or stent graft infection on early follow-up. Direct surgical repair carries
a high risk of enterocutaneous fistula. ( J Vasc Surg 2012;55:1072-80.)
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cThe ureter crosses over the common or proximal exter-
nal iliac artery at the pelvic rim. Ureteral erosion or fistula
into the iliac artery or adjacent organs is a rare but recog-
nized complication in patients with prior pelvic operations,
radiation, indwelling ureteral stents, or arterial prosthetic
grafts. Although the communication typically involves only
the ureter and the iliac artery, complex fistulas can affect the
small bowel, colon, bone, or skin.
Conventional treatment of ureteral-iliac artery fistula
(UIAF) involves extra-anatomic reconstruction with exclu-
sion of the iliac artery; or less frequently, direct arterial
reconstruction with in situ bypass or primary arterial repair.
Ureteral diversion and exclusion without arterial repair is a
palliative measure and does not prevent recurrent bleeding.
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1072ndovascular treatment with stent grafts is a minimally
nvasive alternative, immediately controls bleeding, avoids
issection in a scarred field, and has clear advantages for
atients with hostile anatomy. However, stent grafts fail to
ddress the communication between the ureter and the
rtery, which remains a potential nidus for infection of the
essel and stent graft. Although some reports of endovas-
ular treatment for UIAF suggest this approach is safe and
ffective in select cases, the risk of stent graft infection and
ecurrent bleeding has not been determined. The purpose
f this study was to review changes in treatment strategies
nd outcomes of open surgical repair, hybrid approaches,
nd endovascular treatment of UIAF in a single-center.
ETHODS
The study was approved by the Institutional Review
oard of the Mayo Clinic. We identified 20 consecutive
atients treated for 21 UIAFs by open surgical repair,
ybrid, or endovascular techniques between 1996 and
010. Demographics, cardiovascular risk factors, clinical
resentation, imaging, and operative details were collected
rom the patients’ records. Early and late medical and
urgical morbidity and mortality were recorded. Early out-
ome was defined as the period occurring in the hospital
tay or within 30 postoperative days. Late mortality data
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Volume 55, Number 4 Malgor et al 1073included the use of the Social Security death index search
(http://ssdi.rootsweb.ancestry.com/).
Treatment of UIAF evolved at our institution during the
study period. Treatment in the 1990s was extra-anatomic
reconstruction with a femoral crossover graft and iliac
artery exclusion by coil embolization or direct arterial liga-
tion. This remains the treatment of choice in patients with
local sepsis requiring surgical drainage. Direct arterial repair
was used in patients with inadvertent bleeding encountered
during open urologic procedures, or in the rare patient with
concomitant aneurysmal disease in whom it was important
to maintain pelvic flow into the internal iliac artery. During
the last decade, iliac stent grafts have been preferentially
used to exclude the fistulous communication, except for
patients with abscess or enteric communication.
Statistical analysis. Survival curves were analyzed us-
ing Kaplan-Meier estimates and differences were deter-
mined by Log-rank test. Continuous variables were re-
ported as mean and standard deviation, and categorical
variables as frequency and percentages. A P value less than
.05 was considered statistically significant and all statistical
analyses were performed by JMP 7.01 SAS (SAS Institute,
Cary, NC).
RESULTS
Clinical presentation
There were 15 female and five male patients with the
mean age of 63 13 years (range, 42-88). All patients had
frank hematuria (Table I), which was associated with mas-
sive bleeding, defined by bleeding with severe hypotension
(systolic blood pressure 80 mm Hg) present in 10 pa-
tients (50%). The remaining five patients had intermittent
hematuria requiring transfusion (Table II). Renal insuffi-
ciency was noted in 10 patients (50%) and was chronic in
eight and acute in three.
Predisposing factors for UIAF were present in all pa-
tients and included pelvic operations for malignancy in 18,
pelvic irradiation in 15, indwelling ureteral stents in 15, and
iliofemoral prosthetic grafts in three. The average time from
the previous pelvic operation to presentation was 80  8
months. All patients with indwelling ureteral stents had a
history of hydronephrosis with ureteral strictures caused by
prior irradiation or local operation. Ureteral stents were
placed an average of 4.8  6.1 months prior to presenta-
tion. Eight patients (40%) had recurrent urinary tract infec-
tions treated with chronic oral antibiotic suppression.
Diagnostic investigation
All patients underwent diagnostic studies to identify
the source of bleeding. Cystoscopy was performed in 14
patients (70%) and showed pulsatile flow into the bladder
or fresh thrombus within the ureteral stent in 11 (79%).
Three patients (21%) developed massive bleeding precipi-
tated by intentional cystoscopic manipulation of the ure-
teral stent. Contrast-enhanced computed tomography (CT)
was obtained in eight patients and showed active bleeding
in three. Conventional angiography was utilized in 14 iatients (70%), most often at the time of endovascular
reatment (Fig 1). In two patients, angiography did not
dentify active bleeding into the ureter, but a UIAF was
uspected because of hematuria, the presence of ureteral
tent, prior pelvic radiation, and no other identifiable
ource of bleeding.
The location of 19 UIAFs were confirmed in 18 patients
85%). The fistula affected the left side in 10 patients, right
ide in seven patients, and both sides in one. The fistula
nvolved the common iliac artery in nine patients, the external
liac artery in six, and iliac bifurcation or internal iliac in three.
ne patient had a complex UIAF fistula, which also involved
he sigmoid colon, psoas muscle, and the skin.
reatment
Patients were treated by one of the following ap-
roaches described below and summarized in Table III.
Ureteral diversion and interruption without arte-
ial intervention. An 87-year-old male patient with ad-
anced metastatic colon cancer, myelodysplastic syndrome,
rior aortic reconstruction, sigmoid colectomy, and in-
welling ureteral stents developed left UIAF involving the
ortoiliac graft limb. The patient underwent diverting ne-
hrostomy tube placement, left ureteral embolization, and
o arterial intervention because of advanced metastatic
isease. The hematuria resolved and the patient expired at 8
onths of follow-up.
Direct iliac artery repair. Three patients had direct
able I. Demographics and cardiovascular risk factors in
0 patients treated for ureteral-iliac artery fistulas (UIAFs)
UIAF (N 20
patients)
emographics
Age, years 63  13
Female/male 15/5
ymptoms
Hematuria 20 100%
Massive 10 50%
Dysuria 9 45%
Flank pain 4 20%
ardiovascular risk factors
Coronary artery disease 10 50%
Chronic renal failure 8 40%
Hypertension 9 45%
Smoking 7 35%
Peripheral arterial disease 7 35%
Hyperlipidemia 4 20%
Diabetes mellitus 4 20%
Dialysis 0 0
edications
Beta-blocker 3 15%
ACEi 3 15%
Immunosuppressors
(prednisone, chemotherapy)
3 15%
Coumadin 1 5%
SA classification
ASA 3-4 class 15 75%
CEi, Angiotensin converting-enzyme inhibitor;ASA, American Society of
nesthesiology.liac artery repair. In two, bleeding occurred during
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April 20121074 Malgor et aldissection of the ureter and iliac artery, revealing the
fistulous communication to the iliac artery uncovering
the fistula. In both patients, the arterial defect was
repaired by pledged sutures and covered with omentum.
A third patient developed an UIAF from a pseudoaneu-
Table II. Clinical presentation, underlying diagnosis, and
artery fistulas (UIAFs)
Pt (year) Age, gender
Hematuria/flank pain
(Y/N) Dia
1 (1996) 77F Massive, Y Endometrial
2 (1996) 45F Intermittent, N R Ao-iliac 
crossover
3 (1998) 51F Massive, Y Pelvic myxoid
4 (1998) 71F Massive, N Vulvar cance
5 (1998) 76M Massive, N Rectum canc
6 (1999) 64F Massive, Y Colon cancer
7 (2001) 63F Intermittent, Y Ovarian canc
8 (2003) 87F Massive, N Rectum canc
9 (2004) 88M Massive, Y Bladder canc
10 (2004) 75F Intermittent, N ABI
11 (2006) 60F Massive, N Endometrial
12 (2006) 80M Intermittent, N Rectum canc
13 (2007) 42M Intermittent, N Colon cancer
14 (2007) 56F Intermittent, N Retroperiton
15 (2008) 82M Intermittent, N Bladder canc
conduit)
16 (2008) 65F Intermittent, N Endometrial
17 (2008) 65F Massive, N Recurrent ce
18 (2008) 52F Intermittent, Y Cervical canc
19 (2010) 72F Massive, Y Cervical canc
20 (2010) 68F Intermittent, N Rectum canc
ABI, Aorto-bi-iliac grafts; Ao-iliac, aortoiliac graft; cGy, centigray; fem-fem,
Fig 1. Technique of endovascular treatment of ureteral
obvious extravasation of contrast in the crossing point of
tion of the fistulous communication demonstrates contr
black arrow). The patient was treated with covered b
external iliac artery (D, black arrow) preserving flow intrysm at the distal anastomosis of an aortoiliac graft limb. phis was reconstructed with an in situ rifampin-soaked
olyester graft so that the internal iliac artery could be
reserved, since the contralateral internal iliac artery was
hronically occluded.
Femoral crossover bypass and iliac exclusion. Five
isposing factors in 20 patients treated for ureteral-iliac
Ureteral stent
Radiation dose
(cGy)
Interval from index
diagnosis (months)
r Bilateral 0 168
em No 0 30
sarcoma Unilateral 4500 65
Unilateral 6000 102
No Unk 111
Unilateral 1500 113
No 0 1
ABI Unilateral 0 33
Unilateral 5400 305
Unilateral 0 68
r Unilateral 6120 80
Unilateral Unk 181
Unilateral Unk 65
rcoma Unilateral 1250 37
al No Unk 39
r No 0 3
cancer Unilateral Unk 30
Unilateral 1344 12
Unilateral 3000 144
Unilateral Unk 96
ral-femoral crossover graft; R, right.
artery fistula (UIAF). Right iliac angiography reveals no
reteral stent (A, black arrow), but selective catheteriza-
travasation into the right ureter and ureteral stent (B,
n-expandable stent (C), which was deployed in the
internal iliac artery.pred
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Volume 55, Number 4 Malgor et al 1075artery exclusion using coil embolization in three, or direct
arterial ligation in two. Direct arterial ligation was done
because of a large iliac artery pseudoaneurysm in one, and a
complex fistula with enteric communication and overt in-
fection. The femoral crossover grafts were externally sup-
ported polytetrafluoroethylene (PTFE) graft in three pa-
tients, and polyester or rifampin-soaked polyester graft in
one patient each. One patient with a complex fistula involv-
ing the sigmoid colon and ureter presented in extremis with
hemorrhagic shock 3months after placement of an external
iliac artery stent graft in another institution (Fig 2). This
patient underwent emergent angiography, which con-
firmed complete disruption of the midportion of the iliac
stent graft and iliac artery. The patient was treated with a
new iliac stent graft as a “bridge” to definitive repair, which
included staged femoral crossover graft followed by lapa-
rotomy, sigmoid colectomy, colostomy, ureteral conduit,
and ligation and excision of the infected external iliac artery
and stent graft.
Endovascular iliac artery stent graft. Endovascular
iliac artery stent grafts were used first in 2004. Since then,
Table III. Fistulous location, treatment and outcomes in
Pt (year) UIAF location Type of treatment Nephrostomy tub
1 (1996) L IIA DIR  omental
patch
Yes
2 (1996) R iliac graft In situ R iliac
graft
Prior nephrecto
3 (1998) R EIA Fem-fem  CIA
embo
Yes
4 (1998) L CIA Fem-fem  CIA
embo
No
5 (1998) L CIA Fem-fem  CIA
embo
crossover
Yes
6 (1999) R IIA DIR  omental
patch
No
7 (2001) L CIA Fem-fem  CIA
ligation
No
8 (2003) L iliac graft L endoureteral
embo
Yes
9 (2004) R EIA R iliac SG Yes
10 (2004) L iliac graft L iliac SG Yes
11 (2006) L CIA L iliac SG No
12 (2006) L CIA Aortic endograft
limb
Yes
13 (2007) L EIA L iliac SG Yes
14 (2007) R EIA R iliac SG No
15 (2008) L CIA; R EIA Bif endograft No
16 (2008) R CIA R iliac SG No
17 (2008) R IIA R iliac SG No
18 (2008) R CIA R iliac SG No
19 (2010) L EIA L iliac SG No
Fem-fem  EIA
ligation
20 (2010) L CIA L iliac SG No
Bif, Bifurcated; CIA, common iliac artery; DIR, direct iliac repair; EC, e
femorofemoral crossover graft; F/U, follow-up; IIA, internal iliac artery; L, le
PTC, percutaneous; R, right; SG, stent graft.this technique was applied as the definitive method of areatment in 11 of the 12 patients treated for UIAFs (Table
V). One patient described above had iliac stent graft as a
bridge” to control massive bleeding prior to definitive
reatment by femoral crossover graft and iliac artery exclu-
ion. Of the 11 patients treated definitively by iliac stent
rafts, six presented with massive hematuria and severe
ypotension. A transfemoral percutaneous approach was
sed in all patients with closure devices if sheath diameter
xceeded 8F. Self-expandable stent grafts were used in nine
liac segments, and balloon-expandable stent grafts in two
Table IV). The internal iliac artery was excluded in nine
atients, by the stent graft coverage in five or by coil
mbolization in four. Eight of the 11 patients treated with
tent grafts received chronic oral antibiotic suppression.
arly outcomes
There were no operative deaths. Of the eight patients
reated by direct artery repair or femoral crossover recon-
truction, five (63%) developed complications (Table III).
hese included three (60%) enterocutaneous fistulas,
hich developed because of inadvertent enterotomies
atients treated for ureteral-iliac artery fistulas (UIAFs)
N) Early complications
Late complications/follow-up
(months)
None None at 3 months
EC fistula Graft infection at 1 month/died at
30 months
Wound infection Died at 101 months
None Died at 2 months
None Died at 98 months
EC fistula None at 115 months
EC fistula Died at 2 months
None Died at 8 months
None Died at 6 months
NSTEMI Died at 42 months
None Died at 3 months
None None at 2 months
Stent thrombosis None at 3 months
None Thrombosis at 32 months
None None at 5 months
None None at 13 months
Pneumonia Died at 5 months
Buttock
claudication
None at 14 months
Wound infection None at 3 months
None None at 3 months
utaneous fistula; EIA, external iliac artery; embo, embolization; Fem-fem,
TEMI, non-ST elevationmyocardial infarction; pseudoan, pseudoaneurysm;20 p
e (Y/
my
nterocmong five patients who had laparotomy or flank incisions
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April 20121076 Malgor et alfor direct arterial repair or direct iliac ligation. Two patients
developed superficial wound infections and were treated
with antibiotics. There were no early graft infections after
open surgical reconstructions.
Early complications occurred in three of the 11 patients
Fig 2. Patient with complex ureteral-iliac artery fistula
hematuria and exsanguinating hemorrhage 3 months af
other institution. Left iliac angiography (A) demonstr
extravasation of contrast into the retroperitoneum. A cath
The patient was treated by placement of a self-expandable
(C) also confirmed communication of the rectum with th
subsequently underwent staged right-to-left femoral cros
the left external iliac artery, ureteral conduit, colectomy,
Table IV. Procedural details in 12 patients treated by
endovascular iliac stent grafts for ureteral-iliac artery
fistulas (UIAFs)
Pt Type of stent Diameter (mm)
Embolization
of the IIA
9 (2004)a Wallgrafta 10  50 No
10 (2004) Wallgraft 12  50 No
11 (2006) Viabahnb 10  50 No
12 (2006) Excluderb (limb) 16  100 No
13 (2007) iCastc 7  38 No
14 (2007) iCast 7  38 No
15 (2008) Bifurcated
Excluderb
23  16 Yes
16 (2008) Viabahn 10  50 No
17 (2008) Viabahn 6  100 Yes
18 (2008) Fluencyd 10  60 Yes
20 (2010) Fluency 10  60 Yes
IIA, Internal iliac artery.
aBoston Scientific, Bloomington, Minn.
bW. L. Gore, Flagstaff, Ariz.
cAtrium, Hudson, NH.
dBard,Convington, Ga.(27%) treated with iliac artery stent grafts, including minor pneumonia, non-ST-segment myocardial infarction and
arly stent graft thrombosis in one patient each. The latter
atient had peritoneal carcinomatosis from colon cancer,
nd presented with acute occlusion of a balloon-expand-
ble iCAST stent graft (Atrium, Hudson) placed in the
ommon and external iliac artery. This patient was not on
ny antiplatelet therapy and had a moderate kink of the
tent graft at the transition from the common to the
xternal iliac artery. He was treated successfully by throm-
olysis, redo stent placement and antiplatelet therapy, and
he iliac artery remains patent 20 months later. The mean
ength of hospital stay was 33.6  10.4 days for patients
reated by direct arterial repair, 12  9 days for those who
ad femoral crossover graft, and 11  7 days for iliac stent
rafts (P  .007).
ate outcomes
All patients had clinical and imaging follow-up at a
edian of 14months (range from 2 to 115months). There
ere no recurrent episodes of massive hematuria. However,
ntermittent low grade bleeding or microscopic hematuria
ccurred in three patients (15%). Freedom from any hema-
uria at 3 years was 80% 9% (Fig 3). Fourteen patients had
ermanent indwelling ureteral J stents, which were present
rior to treatment for the UIAF. These stents were ex-
hanged every 3 to 4 months on average.
There were no stent graft infections among the 11
F) with erosion into the rectum presented with massive
dovascular treatment by self-expandable stent graft at
disruption of the left iliac artery and stent graft with
as used to traverse the disrupted stent (A, black arrow).
graft (B) as a bridge to definitive repair. Contrast enema
plex abscess in the retroperitoneum space. The patient
bypass, followed by abdominal exploration, resection of
colostomy.(UIA
ter en
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the sigmoid colon, developed overt infection and disrup-
tion of the external iliac artery and the stent graft (Fig 2).
Another patient with history of chronic recurrent urinary
tract infections had persistent fever and leukocytosis for one
month after stent graft placement, but these problems
resolved with antibiotic suppression. No patient required
explantation of a stent graft or additional treatment because
of periarterial fluid or abscess.
One patient developed late iliac stent graft occlusion at
32 months follow-up, which was likely related to tumor
encasement of the stented iliac artery segment resulting in
compression and then occlusion. This patient was not on
any antiplatelet therapy. Treatment included femoral cross-
over bypass without other complications. Primary and sec-
ondary patency for iliac stent grafts at 2 years was 92% 9%
and 100%, respectively (Fig 4, A and B).
No patient developed stenosis or occlusion after femo-
ral crossover bypass or direct arterial repair. However, one
patient had revision of the femoral anastomosis because of
a noninfected femoral anastomotic pseudoaneurysm. An-
other patient treated initially with in situ rifampin-soaked
graft, developed an enterocutaneous fistula and graft infec-
tion 24 months later, which required complete graft exci-
sion and replacement using cryopreserved arterial allograft.
There were 10 (50%) late deaths, none related to the
UIAF or the procedure. The most common cause of death
was progression of underlying cancer in eight patients, and
cardiac or unknown cause in one patient each. Patient
survival at 1 and 5 years was 75%  10% and 35%  15%,
significantly less than the expected survival for the age- and
gender-matched controls from theMinnesota general pop-
ulation (P  .001; Fig 5).
DISCUSSION
UIAFs are rare and difficult problems to treat. The only
systematic review published by Bergqvist and associates
analyzed 80 patients in 77 reports1 that spanned seven
Fig 3. Kaplan-Meier survival estimates of freedom from hematu-
ria in 20 patients treated for ureteral-iliac artery fistulas (UIAFs).decades. Erosion of the ureter into the iliac artery is hrecipitated by local factors that promote chronic pres-
ure or adherence between the ureter and the artery, or
reteral and arterial fragility from ischemia and radiation
amage. Since most surgeons have treated isolated cases,
reatment algorithms have not yet been defined. The time-
ig 4. Kaplan-Meier survival estimates of primary (A) and sec-
ndary (B) patency rates in 20 patients treated for ureteral-iliac
rtery fistulas (UIAFs) with endovascular stent grafts.
ig 5. Kaplan-Meier patient survival estimates in patients treated
or ureteral-iliac artery fistula (UIAF) and for control patients from
he general population of the State of Minnesota (MN).onored method of reconstruction is femoral crossover
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April 20121078 Malgor et albypass through a noninfected field and iliac artery exclu-
sion. This study shows promising results from endovascular
stent graft coverage to effectively exclude the fistula.
The clinical features of UIAFs deserve comment. These
predominantly affect women (72%) with a wide time range
between the initial operative insult to the ureter and fistu-
lization, ranging from 2 to 25 years in several reports.1
Factors that should raise suspicion of an UIAF include
hematuria in a patient with indwelling ureteral stents, prior
pelvic operations, irradiation, or prior aortoiliac or aorto-
femoral grafts.2-6 In this series, massive hematuria was
common (45%), but was typically associated with herald
bleeding or gross hematuria during ureteral stent manipu-
lations.1,6,7 Therefore, if an UIAF is suspected, manipula-
tions of the ureter should be performed in the endovascular
suite or operating room where immediate arterial control
with percutaneous endovascular techniques is readily avail-
Fig 6. Proposed diagnostic and treatment algoritable. Nonetheless, ureteral stent manipulations are often a secessary maneuver to confirm the diagnosis and demon-
trate the exact location of the fistula.
The diagnostic goal is to identify the specific location of
he fistula into the iliac artery, which is challenging in
atients with intermittent bleeding, bilateral ureteral stents,
r prior aortoiliac or aortofemoral grafts (Fig 6). Blood in
ne or both ureters on cystoscopy may help guide treat-
ent, but is a nonspecific sign.1,2,7,8 A useful maneuver in
reparation for angiography is to exchange the J ureteral
tent for a straight catheter, so that this could be manipu-
ated at time of angiography to induce bleeding and iden-
ify the side and location of the fistula. A straight catheter is
sually able to stop or minimize any bleeding that occurs.
owever, while doing this maneuver, it is imperative that
ne does not loose access in the ureter, and that an endo-
ascular suite and team is immediately available to deal with
ny massive bleeding. The accuracy of tests to locate a
r dealing with ureteral-iliac artery fistula (UIAF).ource of massive urinary bleeding has varied in previous
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Volume 55, Number 4 Malgor et al 1079reports.1,2,7,8 Computed tomographic angiography (CTA)
showed contrast extravasation in only three of eight patients
(38%). However, CTA is useful because it identifies periar-
terial fluid, an abscess, enteric communication, aneurysmal
dilatation and arterial diameter, calcification and thrombus.
Diagnostic angiography with selective iliac views remains
the gold standard. A useful maneuver is to probe the
location where the ureter (or stent) crosses the artery with
a selective catheter, which often shows contrast extravasa-
tion into the ureter (Fig 1). Provocative maneuvers, includ-
ingmanipulation of the ureteral stent as described above, or
administration of thrombolytics can be attempted, but one
must be prepared to immediately deal with massive bleed-
ing triggered by these maneuvers.7 Finally, a minority of
patients (10%) in this report was treated empirically for
UIAF without identification of the exact fistula location.
These individuals had significant hematuria, predisposing
factors for UIAF (ureteral stents, irradiation), and no other
identifiable source of urinary bleeding.
The ideal treatment for UIAF is controversial and has
changed with the advent of covered stents. This report
provides important insight into a variety of methods. Treat-
ment selection is based on patient comorbidities, clinical
presentation, hostile anatomy, presence of overt infection
or enteric contamination, and on the status of pelvic perfu-
sion.9 The ideal treatment should address three primary
goals: control of bleeding, control of sepsis, and repair of
the fistulous communication. Ureteral diversion with per-
cutaneous nephrostomy and endoureteral occlusion with-
out arterial repair is possible, but has been associated with
recurrent bleeding and has the shortcomings of external
ureteral diversion. This technique was used in only one of
our patients in 2003 as a palliative measure because of
advanced cancer. We do not recommend its use when
arterial repair can be performed using endovascular or open
techniques. Traditionally, the most common reconstruc-
tion is a femoral crossover graft and iliac artery exclusion.
Direct primary repair of the iliac artery or arterial ligation
should be avoided because dissection through scarred and
radiated field risks bowel injury and arterial complications.
Our study shows an exceedingly high rate of enterocutane-
ous fistula with the latter approach, in which three of five
(65%) patients developed enteric fistula.
Endovascular coverage of the fistula with stent grafts is
a less-invasive alternative and can be performed percutane-
ously under local anesthesia in most patients. It provides
rapid control of hemorrhage and avoids operating in hostile
abdomen. This technique may decrease trauma, reduce
physiologic stress, and avoids the complications of reopera-
tive surgery in a radiated or scared field. However, stent
grafts fail to address the fistulous communication between
the ureter and the artery, which remains a nidus for bacte-
rial growth and infection. In this study, one patient with
communication to the sigmoid colon failed treatment with
stent grafts, and disrupted the external iliac artery and stent
graft (Fig 2). This problem also has been described with
treatment of aortoenteric erosions with stent grafts, where
failure due to reinfection occurs in 40% of patients and is sssociated with high morbidity and mortality rates.10 For
his reason, we avoid the use of stent grafts as a definitive
ethod of repair in patients with enteric communications
henever possible. However, we use them in extreme situa-
ions as a “bridge” to open surgical repair under more con-
rolled circumstances (Fig 2). Nevertheless, the use of iliac
tent grafts is safe, effective, and has low arterial and stent graft
nfection rates at an average of 2-year follow-up in the absence
f enteric communication. Late follow-up is needed to deter-
ine rates of secondary interventions and risk of infection.
Choice of the stent graft needs to take into consideration
he location of the fistula (common vs external iliac artery),
nd whether there is a discrepancy in arterial diameters.
everal stent graft options that are commercially available
re shown in Table III. Our preference is to use a self-
xpandable stent graft in the external iliac artery position
nd a balloon-expandable stent if there is difference in
iameter between the common and external iliac arteries.
hese can be dilated up to 14 mm. Other alternatives in
hese situations include flared stent grafts or aortic stent
raft limbs.11 Finally, in patients with large diameter vessels
r aneurysms, iliac extension limbs or a bifurcated modular
ortic stent graft may be required.
Patients treated with stent grafts probably warrant
ong-term prophylactic antibiotics, an adjunct used in eight
44%) of 11 patients in this study. While intuitively benefi-
ial, there is no data in the literature to support its efficacy,
osing of suppressive antibiotics, nor the treatment dura-
ion to prevent stent graft infections. Chronic antibiotic
uppression is often needed in patients with indwelling
reteral stents and/or recurrent urinary tract infections.
ne final observation from this report is the occurrence of
wo stent graft occlusions in patients who were not treated
ith antiplatelet therapy after intervention. Our protocol
urrently uses clopidrogel for the first 8 weeks, followed by
spirin indefinitely.
Several shortcomings of our study deserve comment.
ome factors involved in decision-making may have been
issed because of the retrospective design. Patients were
reated by a variety of techniques, and the lack of a pre-
efined treatment algorithm limits generalization of re-
ults. The relatively short follow-up period (median 26
onths) does not allow us to accurately assess long-term
einfection rates, secondary interventions, and stent graft
atency. However, given the rarity of the problem (100
eported cases), this large single-center experience provides
mportant insights about the treatment of UIAF.
ONCLUSIONS
The treatment of UIAF has evolved during the last
ecade. We currently recommend endovascular iliac artery
tent graft coverage as the preferential treatment whenever
ossible. Indications for open reconstruction include en-
eric contamination, abscess, or the need to preserve pelvic
ow because of contralateral occluded or diseased internal
liac artery.
For patients with local sepsis, femoral crossover recon-
truction, and iliac artery exclusion is recommended. Direct
11
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April 20121080 Malgor et alarterial repair or ligation is avoided because of risk of local
complications, but still may be required in a patient who
needs surgical debridement or preservation of pelvic flow.
Early results of iliac stent grafts in select patients with UIAF
is encouraging, but long-term follow-up is needed to de-
termine rates of stent graft infection, patency, and second-
ary interventions.
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